Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- July 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Pillar Clinical Research LLC · Bentonville, AR
California · 1
- CNRI Los Angeles LLC · Pico Rivera, CA
Florida · 1
- Segal Institute for Clinical Research · Miami, FL
Georgia · 1
- CenExel iResearch · Decatur, GA
Illinois · 2
- Pillar Clinical Research LLC · Chicago, IL
- Uptown Research Institute LLC · Chicago, IL
Missouri · 1
- Arch Clinical Trials LLC · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.